Shanghai Institute of Pharmaceutical Industry

Fudan University

Shanghai Hengrui Pharmaceutical Co., Ltd.

Aecc Commercial Aircraft Engine Co., Ltd.

Nhwa Pharma. Corporation

Aecc Shanghai Commercial Aircraft Engine Manufacturing Co., Ltd.

Yali Li

Jianqi Li

Lei Zhang

Yan Chen

Peng Cho Tang

Guan Zhong Wang

Ying Zhou

Guisen Zhang

Xiangqing Xu

Yidong Su

Yongyong Zheng

Minquan Yu

Fuqiang Zhao

Song Zhao

Shicheng Liu

Yong Chu

Xiaowen Chen

Qi Huang

Deyong Ye

Xiaohui Chen

Jialiang Yang

Lu Zhou

Jun Fu

Yunfeng Liao

Penghui Wang

Pingyan Bie

Guangtao Qian

Haojun Gong

Minggang Ju

Zhikuan Zhang

Liming Lei

Yanli He

A method for prefabricating pore defects by controlling a SLM process, including performing laser scanning on a specified metal melt layer (LY) according to a first scan path (P) and a second scan path. The first scan path (P) and the second scan path (P) have a path overlap zone (A), the path overlap zone (A) has a predetermined width, and laser energy input superimposed in the path overlap zone (A) is controlled to reach a predetermined energy value, whereby keyholes are formed at a plurality of positions in a lengthwise direction of the path overlap zone (A), the specified metal melt layer (LY) is taken as a defect layer, and the keyholes in the path overlap zone (A) is taken as pore defects.

Method for prefabricating air hole defect by means of controlled SLM process

2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (SMS) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (SM). The pharmaceutically acceptable salts and pharmaceutical compositions of the compounds are used as active ingredients in drugs which can prevent and cure diseases caused by SM level abnormal increase. These diseases include atherosclerosis, fatty liver, obesity, type diabetes, and other metabolic syndromes.

2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof

Disclosed in the present invention is a 3-cyanoanilinoalkylarylpiperazine derivatives and use thereof in preparing drugs; the 3-cyanoanilinoalkylarylpiperazine derivatives disclosed by the present invention has very useful pharmaceutical properties and good tolerance, especially the use as novel analgesic drugs, novel antidepressants, and novel analgesic and antidepressive drugs. This class of compounds are central analgesics regulating 5-hydroxytrptamine, and also are novel antidepressants regulating 5-hydroxytrptamine. This class of compounds also has less toxic and side effects and a higher safety range. The 3-cyanoanilinoalkylarylpiperazine derivative is a compound shown as formula (III) or free base or salt thereof: 

3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs

Aralkyl diamine derivative of the following formula, pharmaceutically acceptable salts or uses thereof as antidepressants. The derivatives have triplex inhibiting activities of the reuptake of 5-HT, dopamine and noradrenalin, which can be administered to the patients in need of such treatment in the form of compositions orally or injectedly et al. 

Aralkyl diamine derivatives and uses thereof as antidepressants

The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description. 

Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof

Growing community of inventors

Shanghai, China

Yali Li